<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="151306">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01846689</url>
  </required_header>
  <id_info>
    <org_study_id>E130426</org_study_id>
    <nct_id>NCT01846689</nct_id>
  </id_info>
  <brief_title>An Open-label Trial to Determine Increased Red Blood Cell Production in Subjects With Anemia of Chronic Disease</brief_title>
  <official_title>An Open-label Trial of an Erythropoietin Stimulating System to Determine Increased Red Blood Cell Production in Subjects Diagnosed With Anemia of Chronic Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Targeted Medical Pharma</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Targeted Medical Pharma</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to measure the change in blood values after the
      administration of an amino acid based erythropoietin stimulating system.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">September 2013</completion_date>
  <primary_completion_date type="Anticipated">August 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Hemoglogin/Hematocrit</measure>
    <time_frame>28 Days</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Red blood cell count</measure>
    <time_frame>28 Days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reticulocyte count</measure>
    <time_frame>28 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IGF-1</measure>
    <time_frame>28 days</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Anemia of Chronic Disease</condition>
  <arm_group>
    <arm_group_label>ESS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Prescription medical food erythropoietin stimulating system</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ESS (medical food/drug)</intervention_name>
    <description>Prescription medical food erythropoietin stimulating system</description>
    <arm_group_label>ESS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. M/F patients 18 years old and over, non-pregnant/lactating

          2. Hemoglobin &lt; 10 female,&lt;11 male

          3. Ferritin &gt; upper limit of normal for lab indicative of chronic anemia

          4. Anemia of chronic disease

          5. Crt. &lt; 3.0

        Exclusion Criteria:

          1. Currently taking other amino acid formulations.

          2. Pregnant or unwilling to use adequate birth control for the duration of the study.

          3. Excessive alcohol or illicit drug use.

          4. Unwilling or unable to sign informed consent.

          5. Myocardial infarction within the last 6 months.

          6. Patients ever having taken or currently taking an erythropoietin medication.

          7. Iron deficiency (add criteria).

          8. On dialysis.

          9. Malignancy other than non-melanoma skin cancer within the last 5 years. If has such
             malignancy, must have documentation of no recurrence for at least 5 years.

         10. Liver cirrhosis (add criteria).
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Stephanie Pavlik, CRA</last_name>
    <phone>310-474-9809</phone>
    <email>spavlik@ptlcentral.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Targeted Medical Pharma</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90077</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Stephanie Pavlik, CRA</last_name>
      <phone>310-474-9809</phone>
      <email>spavlik@ptlcentral.com</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2013</verification_date>
  <lastchanged_date>April 30, 2013</lastchanged_date>
  <firstreceived_date>April 30, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Anemia</mesh_term>
    <mesh_term>Chronic Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Epoetin Alfa</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
